7 701

Cited 23 times in

Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model

DC Field Value Language
dc.contributor.author이현철-
dc.contributor.author정태우-
dc.contributor.author차봉수-
dc.contributor.author강은석-
dc.contributor.author안철우-
dc.date.accessioned2014-12-21T17:12:18Z-
dc.date.available2014-12-21T17:12:18Z-
dc.date.issued2007-
dc.identifier.issn0026-0495-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/97143-
dc.description.abstractTreatment with rosiglitazone, a potent peroxisome proliferator–activated receptor (PPAR) γ agonist, results in lipid storage coupled with reduced release of free fatty acids into the circulation. Many studies have reported that PPAR-γ agonists increase subcutaneous adiposity but have no effect on visceral fat mass. Perilipin, a family of phosphoproteins that coat intracellular lipid droplets in adipocytes, is essential for enlargement of lipid droplets. Recently, a functional PPAR-responsive element was identified within the murine perilipin gene. We hypothesized that the depot-specific regulation of perilipin by rosiglitazone may be associated with the fat-redistribution and insulin-sensitizing effects of rosiglitazone. After 6 weeks of rosiglitazone treatment in Otusuka Long-Evans Tokushima Fatty rats, an animal model of type 2 diabetes mellitus, we measured changes in adiposity, triglyceride content in liver and muscle, morphology of the pancreas, and perilipin messenger RNA and protein expression in adipose tissue. Rosiglitazone increased subcutaneous adiposity, decreased triglyceride content of liver and muscle, decreased plasma free fatty acids (2107 ± 507 μmol/L in the placebo group vs 824 ± 148 μmol/L in the rosiglitazone group; P < .05), and improved insulin resistance. The islets of placebo-treated rats showed hypertrophy and destruction, whereas the islets of rosiglitazone-treated rats showed hypertrophy, but the islet architecture remained intact. Perilipin messenger RNA and protein expression increased in subcutaneous fat, but did not change in visceral fat, after rosiglitazone treatment. In 3T3-L1 cells, rosiglitazone pretreatment decreased lipolysis and increased perilipin protein. In conclusion, increased perilipin expression in subcutaneous fat after rosiglitazone treatment is likely to be a mediator of reduced lipolysis, resulting in lipid storage in subcutaneous fat, fat redistribution, and insulin sensitization.-
dc.description.statementOfResponsibilityopen-
dc.format.extent676~685-
dc.relation.isPartOfMETABOLISM-CLINICAL AND EXPERIMENTAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleDepot-specific regulation of perilipin by rosiglitazone in a diabetic animal model-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorHae Jin Kim-
dc.contributor.googleauthorTae Woo Jung-
dc.contributor.googleauthorBong Soo Cha-
dc.contributor.googleauthorHyun Chul Lee-
dc.contributor.googleauthorKwan Woo Lee-
dc.contributor.googleauthorChul Woo Ahn-
dc.contributor.googleauthorDae Jung Kim-
dc.contributor.googleauthorEun Seok Kang-
dc.identifier.doi10.1016/j.metabol.2006.12.017-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03301-
dc.contributor.localIdA03752-
dc.contributor.localIdA03996-
dc.contributor.localIdA00068-
dc.contributor.localIdA02270-
dc.relation.journalcodeJ02223-
dc.identifier.eissn1532-8600-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0026049507000418-
dc.contributor.alternativeNameLee, Hyun Chul-
dc.contributor.alternativeNameJung, Tae Woo-
dc.contributor.alternativeNameCha, Bong Soo-
dc.contributor.alternativeNameKang, Eun Seok-
dc.contributor.alternativeNameAhn, Chul Woo-
dc.contributor.affiliatedAuthorLee, Hyun Chul-
dc.contributor.affiliatedAuthorJung, Tae Woo-
dc.contributor.affiliatedAuthorCha, Bong Soo-
dc.contributor.affiliatedAuthorKang, Eun Seok-
dc.contributor.affiliatedAuthorAhn, Chul Woo-
dc.rights.accessRightsnot free-
dc.citation.volume56-
dc.citation.number5-
dc.citation.startPage676-
dc.citation.endPage685-
dc.identifier.bibliographicCitationMETABOLISM-CLINICAL AND EXPERIMENTAL, Vol.56(5) : 676-685, 2007-
dc.identifier.rimsid55203-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.